Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.

Chen Q, Perales C, Soria ME, García-Cehic D, Gregori J, Rodríguez-Frías F, Buti M, Crespo J, Calleja JL, Tabernero D, Vila M, Lázaro F, Rando-Segura A, Nieto-Aponte L, Llorens-Revull M, Cortese MF, Fernandez-Alonso I, Castellote J, Niubó J, Imaz A, Xiol X, Castells L, Riveiro-Barciela M, Llaneras J, Navarro J, Vargas-Blasco V, Augustin S, Conde I, Rubín Á, Prieto M, Torras X, Margall N, Forns X, Mariño Z, Lens S, Bonacci M, Pérez-Del-Pulgar S, Londoño MC, García-Buey ML, Sanz-Cameno P, Morillas R, Martró E, Saludes V, Masnou-Ridaura H, Salmerón J, Quíles R, Carrión JA, Forné M, Rosinach M, Fernández I, García-Samaniego J, Madejón A, Castillo-Grau P, López-Núñez C, Ferri MJ, Durández R, Sáez-Royuela F, Diago M, Gimeno C, Medina R, Buenestado J, Bernet A, Turnes J, Trigo-Daporta M, Hernández-Guerra M, Delgado-Blanco M, Cañizares A, Arenas JI, Gomez-Alonso MJ, Rodríguez M, Deig E, Olivé G, Río OD, Cabezas J, Quiñones I, Roget M, Montoliu S, García-Costa J, Force L, Blanch S, Miralbés M, López-de-Goicoechea MJ, García-Flores A, Saumoy M, Casanovas T, Baliellas C, Gilabert P, Martin-Cardona A, Roca R, Barenys M, Villaverde J, Salord S, Camps B, Silvan di Yacovo M, Ocaña I, Sauleda S, Bes M, Carbonell J, Vargas-Accarino E, Ruzo SP, Guerrero-Murillo M, Von Massow G, Costafreda MI, López RM, González-Moreno L, Real Y, Acero-Fernández D, Viroles S, Pamplona X, Cairó M, Ocete MD, Macías-Sánchez JF, Estébanez A, Quer JC, Mena-de-Cea Á, Otero A, Castro-Iglesias Á, Suárez F, Vázquez Á, Vieito D, López-Calvo S, Vázquez-Rodríguez P, Martínez-Cerezo FJ, Rodríguez R, Macenlle R, Cachero A, Mereish G, Mora-Moruny C, Fábregas S, Sacristán B, Albillos A, Sánchez-Ruano JJ, Baluja-Pino R, Fernández-Fernández J, González-Portela C, García-Martin C, Sánchez-Antolín G, Andrade RJ, Simón MA, Pascasio JM, Romero-Gómez M, Antonio Del-Campo J, Domingo E, Esteban R, Esteban JI, Quer J.

Antiviral Res. 2019 Dec 16;174:104694. doi: 10.1016/j.antiviral.2019.104694. [Epub ahead of print]

PMID:
31857134
2.

Breast pectoral muscle segmentation in mammograms using a modified holistically-nested edge detection network.

Rampun A, López-Linares K, Morrow PJ, Scotney BW, Wang H, Ocaña IG, Maclair G, Zwiggelaar R, González Ballester MA, Macía I.

Med Image Anal. 2019 Oct;57:1-17. doi: 10.1016/j.media.2019.06.007. Epub 2019 Jun 20.

PMID:
31254729
3.

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.

Picornell AC, Echavarria I, Alvarez E, López-Tarruella S, Jerez Y, Hoadley K, Parker JS, Del Monte-Millán M, Ramos-Medina R, Gayarre J, Ocaña I, Cebollero M, Massarrah T, Moreno F, García Saenz JA, Gómez Moreno H, Ballesteros A, Ruiz Borrego M, Perou CM, Martin M.

BMC Genomics. 2019 Jun 3;20(1):452. doi: 10.1186/s12864-019-5849-0.

4.

Sexually transmitted infections in young people and factors associated with HIV coinfection: an observational study in a large city.

Sentís A, Martin-Sanchez M, Arando M, Vall M, Barbera MJ, Ocaña I, González Cordón A, Alsina M, Martin-Ezquerra G, Knobel H, Gurguí M, Vives A, Coll J, Caylà JA, Garcia de Olalla P; STI-HIV group of Barcelona.

BMJ Open. 2019 May 5;9(5):e027245. doi: 10.1136/bmjopen-2018-027245.

5.

Neuronal and Glial Differentiation of Human Neural Stem Cells Is Regulated by Amyloid Precursor Protein (APP) Levels.

Coronel R, Lachgar M, Bernabeu-Zornoza A, Palmer C, Domínguez-Alvaro M, Revilla A, Ocaña I, Fernández A, Martínez-Serrano A, Cano E, Liste I.

Mol Neurobiol. 2019 Feb;56(2):1248-1261. doi: 10.1007/s12035-018-1167-9. Epub 2018 Jun 7.

PMID:
29881946
6.

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.

Echavarria I, López-Tarruella S, Picornell A, García-Saenz JÁ, Jerez Y, Hoadley K, Gómez HL, Moreno F, Monte-Millan MD, Márquez-Rodas I, Alvarez E, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, Cebollero M, Fuentes H, Barnadas A, Ballesteros AI, Bohn U, Perou CM, Martin M.

Clin Cancer Res. 2018 Apr 15;24(8):1845-1852. doi: 10.1158/1078-0432.CCR-17-1912. Epub 2018 Jan 29.

7.

Barriers to health care services for migrants living with HIV in Spain.

Ndumbi P, Del Romero J, Pulido F, Velasco Arribas M, Dronda F, Blanco Ramos JR, García de Olalla P, Ocaña I, Belda-Ibañez J, Del Amo J, Álvarez-Del Arco D; aMASE Research Group.

Eur J Public Health. 2018 Jun 1;28(3):451-457. doi: 10.1093/eurpub/ckx225.

PMID:
29325097
8.

Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.

González-Rivera M, Lobo M, López-Tarruella S, Jerez Y, Del Monte-Millán M, Massarrah T, Ramos-Medina R, Ocaña I, Picornell A, Santillán Garzón S, Pérez-Carbornero L, García-Saenz JA, Gómez H, Moreno F, Márquez-Rodas I, Fuentes H, Martin M.

Breast Cancer Res Treat. 2017 Sep;165(2):471. doi: 10.1007/s10549-017-4396-0. No abstract available.

PMID:
28721639
9.

A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients.

Grau-Expósito J, Serra-Peinado C, Miguel L, Navarro J, Curran A, Burgos J, Ocaña I, Ribera E, Torrella A, Planas B, Badía R, Castellví J, Falcó V, Crespo M, Buzon MJ.

mBio. 2017 Jul 11;8(4). pii: e00876-17. doi: 10.1128/mBio.00876-17.

10.

Acute leg ischaemia in an HIV-infected patient receiving antiretroviral treatment.

Navarro J, Curran A, Burgos J, Torrella A, Ocaña I, Falcó V, Crespo M, Ribera E.

Antivir Ther. 2017;22(1):89-90. doi: 10.3851/IMP3075. Epub 2016 Aug 22.

PMID:
27546463
11.

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.

González-Rivera M, Lobo M, López-Tarruella S, Jerez Y, Del Monte-Millán M, Massarrah T, Ramos-Medina R, Ocaña I, Picornell A, Santillán Garzón S, Pérez-Carbornero L, García-Saenz JA, Gómez H, Moreno F, Márquez-Rodas I, Fuentes H, Martin M.

Breast Cancer Res Treat. 2016 Apr;156(3):507-515. doi: 10.1007/s10549-016-3792-1. Epub 2016 Apr 15. Erratum in: Breast Cancer Res Treat. 2017 Sep;165(2):471.

PMID:
27083178
12.

Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment.

Navarro J, Caballero E, Curran A, Burgos J, Ocaña I, Falcó V, Torrella A, Pérez M, Ribera E, Crespo M.

Antivir Ther. 2016;21(4):345-52. doi: 10.3851/IMP3023. Epub 2016 Jan 12.

PMID:
26756461
13.

Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort.

Garriga C, García de Olalla P, Miró JM, Ocaña I, Knobel H, Barberá MJ, Humet V, Domingo P, Gatell JM, Ribera E, Gurguí M, Marco A, Caylà JA; Barcelona HIV/AIDS working group.

PLoS One. 2015 Dec 30;10(12):e0145701. doi: 10.1371/journal.pone.0145701. eCollection 2015.

14.

The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men.

Burgos J, Curran A, Landolfi S, Navarro J, Tallada N, Guelar A, Crespo M, Ocaña I, Ribera E, Falcó V.

HIV Med. 2016 Aug;17(7):524-31. doi: 10.1111/hiv.12352. Epub 2015 Dec 21.

15.

Review: circulating tumor cells in the practice of breast cancer oncology.

Ramos-Medina R, Moreno F, Lopez-Tarruella S, Del Monte-Millán M, Márquez-Rodas I, Durán E, Jerez Y, Garcia-Saenz JA, Ocaña I, Andrés S, Massarrah T, González-Rivera M, Martin M.

Clin Transl Oncol. 2016 Aug;18(8):749-59. doi: 10.1007/s12094-015-1460-2. Epub 2015 Dec 8. Review.

PMID:
26646763
16.

FGF signaling enhances a sonic hedgehog negative feedback loop at the initiation of spinal cord ventral patterning.

Morales AV, Espeso-Gil S, Ocaña I, Nieto-Lopez F, Calleja E, Bovolenta P, Lewandoski M, Diez Del Corral R.

Dev Neurobiol. 2016 Sep;76(9):956-71. doi: 10.1002/dneu.22368. Epub 2015 Dec 8.

17.

Epidemiology of infections by HIV, Syphilis, Gonorrhea and Lymphogranuloma Venereum in Barcelona City: a population-based incidence study.

Martí-Pastor M, García de Olalla P, Barberá MJ, Manzardo C, Ocaña I, Knobel H, Gurguí M, Humet V, Vall M, Ribera E, Villar J, Martín G, Sambeat MA, Marco A, Vives A, Alsina M, Miró JM, Caylà JA; HIV Surveillance Group.

BMC Public Health. 2015 Oct 5;15:1015. doi: 10.1186/s12889-015-2344-7.

18.

Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.

Curran A, Martí R, López RM, Pérez M, Crespo M, Melià MJ, Navarro J, Burgos J, Falcó V, Ocaña I, Ribera E.

Antimicrob Agents Chemother. 2015 Nov;59(11):6782-90. doi: 10.1128/AAC.01099-15. Epub 2015 Aug 17.

19.

Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literature.

López-Sánchez C, Falcó V, Burgos J, Navarro J, Martín MT, Curran A, Miguel L, Ocaña I, Ribera E, Crespo M, Almirante B.

Medicine (Baltimore). 2015 Mar;94(12):e681. doi: 10.1097/MD.0000000000000681. Review.

20.

Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.

Gonzalez FA, Van den Eynde E, Perez-Hoyos S, Navarro J, Curran A, Burgos J, Falcó V, Ocaña I, Ribera E, Crespo M.

HIV Med. 2015 Apr;16(4):211-8. doi: 10.1111/hiv.12197. Epub 2014 Sep 18.

21.

Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.

Navarro J, Pérez M, Curran A, Burgos J, Feijoo M, Torrella A, Caballero E, Ocaña I, Ribera E, Crespo M, Falcó V.

AIDS Patient Care STDS. 2014 Oct;28(10):537-42. doi: 10.1089/apc.2014.0097. Epub 2014 Aug 11.

PMID:
25111167
22.

Progress in stem cell therapy for major human neurological disorders.

Martínez-Morales PL, Revilla A, Ocaña I, González C, Sainz P, McGuire D, Liste I.

Stem Cell Rev Rep. 2013 Oct;9(5):685-99. doi: 10.1007/s12015-013-9443-6. Review.

PMID:
23681704
23.

Tropical diseases screening in immigrant patients with human immunodeficiency virus infection in Spain.

Salvador F, Molina I, Sulleiro E, Burgos J, Curran A, Van den Eynde E, Villar del Saz S, Navarro J, Crespo M, Ocaña I, Ribera E, Falcó V, Pahissa A.

Am J Trop Med Hyg. 2013 Jun;88(6):1196-202. doi: 10.4269/ajtmh.12-0714. Epub 2013 Mar 18.

24.

Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital.

Riveiro-Barciela M, Falcó V, Burgos J, Curran A, Van den Eynde E, Navarro J, Villar del Saz S, Ocaña I, Ribera E, Crespo M, Pahissa A.

HIV Med. 2013 Jan;14(1):21-30. doi: 10.1111/j.1468-1293.2012.01033.x. Epub 2012 Jun 25.

25.

Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009.

de Olalla PG, Manzardo C, Sambeat MA, Ocaña I, Knobel H, Humet V, Domingo P, Ribera E, Guelar A, Marco A, Belza MJ, Miró JM, Caylà JA; HIV Surveillance Group.

AIDS Res Ther. 2011 Jul 6;8(1):22. doi: 10.1186/1742-6405-8-22.

26.

Appropriate Bmp7 levels are required for the differentiation of midline guidepost cells involved in corpus callosum formation.

Sánchez-Camacho C, Ortega JA, Ocaña I, Alcántara S, Bovolenta P.

Dev Neurobiol. 2011 May;71(5):337-50. doi: 10.1002/dneu.20865.

27.

Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.

Curran A, Gutirerrez M, Deig E, Mateo G, Lopez RM, Imaz A, Crespo M, Ocaña I, Domingo P, Ribera E.

J Antimicrob Chemother. 2010 Oct;65(10):2195-203. doi: 10.1093/jac/dkq295. Epub 2010 Aug 16.

PMID:
20713406
28.

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

Imaz A, del Saz SV, Ribas MA, Curran A, Caballero E, Falcó V, Crespo M, Ocaña I, Diaz M, de Gopegui ER, Riera M, Ribera E.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):382-6. doi: 10.1097/QAI.0b013e3181b17f53. Erratum in: J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e102.

PMID:
19654552
29.

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.

Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, Rodríguez-Frias F, Falco V, Curran A, Imaz A, Villar del Saz S, Ocaña I, Esteban R, Pahissa A.

Clin Infect Dis. 2009 Apr 15;48(8):1152-9. doi: 10.1086/597470. Erratum in: Clin Infect Dis. 2009 Aug 1;49(3):489.

PMID:
19275492
30.

Non-tuberculous mycobacteria in the sputum of HIV-infected patients: infection or colonization?

Alvarez-Uria G, Falcó V, Martín-Casabona N, Crespo M, Villar Del Saz S, Curran A, Ocaña I, Ribera E, Pahissa A.

Int J STD AIDS. 2009 Mar;20(3):193-5. doi: 10.1258/ijsa.2008.008300.

PMID:
19255269
31.

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

Ribera E, Paradiñeiro JC, Curran A, Sauleda S, García-Arumí E, Castella E, Puiggròs C, Crespo M, Feijoo M, Diaz M, Del Saz SV, Planas M, Sureda D, Falcó V, Ocaña I, Pahissa A.

HIV Clin Trials. 2008 Nov-Dec;9(6):407-17. doi: 10.1310/hct0906-407.

PMID:
19203906
32.

Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients.

Crespo M, Pou L, Esteban JI, Falcó V, Ribera E, Lopez R, Sauleda S, Curran A, Villar del Saz S, Feijoo M, Ocaña I, Pahissa A.

Antivir Ther. 2007;12(8):1217-23.

PMID:
18240861
33.

Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.

Molina I, Falcó V, Crespo M, Riera C, Ribera E, Curran A, Carrio J, Diaz M, Villar del Saz S, Fisa R, López-Chejade P, Ocaña I, Pahissa A.

J Antimicrob Chemother. 2007 Oct;60(4):837-42. Epub 2007 Aug 7.

PMID:
17684055
34.

Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.

Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, Falco V, Quer J, Ocaña I, Ruiz I, Buti M, Pahissa A, Esteban R, Guardia J.

J Viral Hepat. 2007 Apr;14(4):228-38.

PMID:
17381714
35.

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A.

J Antimicrob Chemother. 2007 Apr;59(4):690-7. Epub 2007 Feb 16.

PMID:
17307771
36.

Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.

Crespo M, Esteban JI, Ribera E, Falco V, Sauleda S, Buti M, Esteban R, Guardia J, Ocaña I, Pahissa A.

AIDS. 2007 Feb 19;21(4):477-81.

PMID:
17301566
37.

[Follow-up of people with HIV].

Feijoo M, Llinás M, Carballo M, Ocaña I.

Rev Enferm. 2006 Apr;29(4):55-8, 60-2. Spanish.

PMID:
16724501
38.

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.

Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocaña I, Pahissa A.

AIDS. 2006 May 12;20(8):1131-9.

PMID:
16691064
39.

Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.

Falcó V, Jordano Q, Cruz MJ, Len O, Ribera E, Campins M, Crespo M, Ocaña I, Rodrigo MJ, Pahissa A.

Vaccine. 2006 Mar 24;24(14):2567-74. Epub 2005 Dec 27.

PMID:
16423429
40.

Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).

Ribera E, Azuaje C, Lopez RM, Domingo P, Soriano A, Pou L, Sánchez P, Mallolas J, Sambea MA, Falco V, Ocaña I, Lopez-Colomes JL, Gatell JM, Pahissa A.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):317-23.

PMID:
16249706
41.

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.

Antivir Ther. 2005;10(5):605-14.

PMID:
16152754
42.

Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A.

Antimicrob Agents Chemother. 2004 Nov;48(11):4256-62.

43.

Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.

Fernandez-Cruz E, Moreno S, Navarro J, Clotet B, Bouza E, Carbone J, Peña JM, Pérez Molina J, Podzamczer D, Rubio R, Ocaña I, Pulido F, Viciana P, Maradona JA, Blazquez R, Barros C, Quereda C, Rodriguez-Sainz C, Gil J, Abad ML, Díaz L, Cantó C, Muñoz MA, Ferrer E, Jou A, Sirera G, Díaz M, Lopez F, Gatell JM, Gonzalez-Lahoz J; STIR-2102 TEAM.

Vaccine. 2004 Aug 13;22(23-24):2966-73.

PMID:
15297045
44.

A case of multiorgan failure following interruption of antiretroviral treatment.

Crespo M, Paradiñeiro JC, Ribera E, Ruiz I, Falcó V, Lopez-Quiñones J, Ocaña I, Pahissa A.

Eur J Clin Microbiol Infect Dis. 2004 Jan;23(1):63-5. Epub 2003 Dec 11.

PMID:
14669071
45.

Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients.

García de Olalla P, Martínez-González MA, Caylà JA, Jansà JM, Iglesias B, Guerrero R, Marco A, Gatell JM, Ocaña I; Barcelona AIDS-TB Study Group.

Int J Tuberc Lung Dis. 2002 Dec;6(12):1051-7.

PMID:
12546112
46.

A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J.

Antivir Ther. 2002 Jun;7(2):81-90.

PMID:
12212928
47.

Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.

Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocaña I, Ruiz I, Pahissa A.

J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):450-3.

PMID:
11744833
48.

Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients.

Ribera E, Pou L, Fernandez-Sola A, Campos F, Lopez RM, Ocaña I, Ruiz I, Pahissa A.

Antimicrob Agents Chemother. 2001 Nov;45(11):3238-41.

49.

[Fexofenadine: a antihistaminic. Review of its practical characteristics].

Caballero E, Ocaña I, Azanza JR, Sádaba B.

Rev Med Univ Navarra. 1999 Apr-Jun;43(2):93-7. Spanish. No abstract available.

PMID:
11256010
50.

Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients.

Ribera E, Fernandez-Sola A, Juste C, Rovira A, Romero FJ, Armadans-Gil L, Ruiz I, Ocaña I, Pahissa A.

Clin Infect Dis. 1999 Dec;29(6):1461-6.

PMID:
10585796

Supplemental Content

Support Center